{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:16:05Z","timestamp":1789748165456,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.rdc.2021.07.009","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:34:51Z","timestamp":1630571691000},"page":"545-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Juvenile Idiopathic Arthritis Treatment Updates"],"prefix":"10.1016","volume":"47","author":[{"given":"Karen","family":"Onel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dax G.","family":"Rumsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shenoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rdc.2021.07.009_bib1","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997","volume":"25","author":"Petty","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.009_bib2","series-title":"Textbook of pediatric rheumatology","first-page":"241","article-title":"Oligoarticular juvenile idiopathic arthritis","author":"Ringold","year":"2020"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.009_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/acr.23853","article-title":"Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic juvenile idiopathic arthritis cohort","volume":"72","author":"Glerup","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2021.07.009_bib4","series-title":"Textbook of pediatric rheumatology","first-page":"228","article-title":"Polyarticular juvenile idiopathic arthritis","author":"Rosenberg","year":"2020"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.009_bib5","first-page":"219","article-title":"Early diagnosis of temporomandibular joint arthritis in children with juvenile idiopathic arthritis. A systematic review","volume":"21","author":"Pawlaczyk-Kamienska","year":"2020","journal-title":"Eur J Paediatr Dent"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.40350","article-title":"Review: genetics and the classification of arthritis in adults and children","volume":"70","author":"Nigrovic","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.009_bib7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.009_bib8","series-title":"Presented at: ACR Convergence; 11\/08\/2020","author":"Onel","year":"2020"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.009_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/kez048","article-title":"Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.009_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/rheumatology\/keh313","article-title":"Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial","volume":"43","author":"Zulian","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.009_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.009_bib12","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3899\/jrheum.200437","article-title":"Biologic switching among non-systemic juvenile idiopathic arthritis patients: a cohort study in the childhood arthritis and rheumatology research alliance registry","volume":"48","author":"Mannion","year":"2021","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/acr.23922","article-title":"Real-world effectiveness of common treatment strategies for juvenile idiopathic arthritis: results from a Canadian cohort","volume":"72","author":"Chhabra","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/acr2.11091","article-title":"Biologic therapies in polyarticular juvenile idiopathic arthritis. comparison of long-term safety data from the German BIKER registry","volume":"2","author":"Klein","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.009_bib15","article-title":"Functional ability and health-related quality of life in randomized controlled trials of tocilizumab in patients with juvenile idiopathic arthritis","author":"Brunner","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.009_bib16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3899\/jrheum.180795","article-title":"Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis","volume":"46","author":"Pardeo","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12969-019-0319-4","article-title":"Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"17","author":"Hara","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"suppl 10","key":"10.1016\/j.rdc.2021.07.009_bib19","article-title":"Tofacitinib for the treatment of patients with juvenile idiopathic arthritis: an interim analysis of data up to 5.5 years from an open-label, long-term extension study [abstract]","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.009_bib20","author":"Kimura","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.009_bib21","article-title":"Improved disease course associated with early initiation of biologics in untreated polyarticular Juvenile Idiopathic Arthritis","author":"Ong","year":"2021","journal-title":"A trajectory analysis of the STOP-JIA study"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.009_bib22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","article-title":"Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis","volume":"79","author":"Klein","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.009_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3899\/jrheum.190268","article-title":"Outcome monitoring and clinical decision support in polyarticular juvenile idiopathic arthritis","volume":"47","author":"Buckley","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.009_bib25","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/art.41390","article-title":"New medications are needed for children with juvenile idiopathic arthritis","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.009_bib26","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.40509","article-title":"Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in children with polyarticular forms of juvenile idiopathic arthritis with clinically inactive disease","volume":"70","author":"Lovell","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib27","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/acr.23435","article-title":"Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration","volume":"70","author":"Simonini","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.009_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.pcl.2018.03.006","article-title":"Juvenile spondyloarthritis: a distinct form of juvenile arthritis","volume":"65","author":"Weiss","year":"2018","journal-title":"Pediatr Clin North Am"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.009_bib29","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1002\/art.22173","article-title":"Patients with juvenile psoriatic arthritis comprise two distinct populations","volume":"54","author":"Stoll","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.009_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3899\/jrheum.160717","article-title":"The juvenile psoriatic arthritis cohort in the CARRA registry: clinical characteristics, classification, and outcomes","volume":"44","author":"Zisman","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.009_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/acr.23844","article-title":"Worse quality of life, function, and pain in children with enthesitis, irrespective of their juvenile arthritis category","volume":"72","author":"Rumsey","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2021.07.009_bib32","series-title":"Textbook of pediatric rheumatology","first-page":"250","article-title":"Enthesitis-related arthritis","author":"Tse","year":"2020"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.009_bib33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/ard.61.10.941","article-title":"A\u00a026\u00a0week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies","volume":"61","author":"Burgos-Vargas","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.009_bib34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T","article-title":"Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group","volume":"41","author":"van Rossum","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib35","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/acr.24537","article-title":"Juvenile spondyloarthritis in the CARRA registry: high biologic use, low prevalence of HLA-B27, and equal sex representation in sacroiliitis","volume":"73","author":"Rumsey","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.009_bib36","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.009_bib37","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3899\/jrheum.150430","article-title":"Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis","volume":"43","author":"Constantin","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10067-014-2744-6","article-title":"Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis","volume":"34","author":"Windschall","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.009_bib39","first-page":"745","article-title":"A\u00a03-month, double-blind, placebo-controlled, randomized trial of infliximab in juvenile-onset spondyloarthritis (SpA) and a 52-week open extension","volume":"26","author":"Burgos-Vargas","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.009_bib40","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ibd\/izy010","article-title":"The impact of combination therapy on infliximab levels and antibodies in children and young adults with inflammatory bowel disease","volume":"24","author":"Chi","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.009_bib41","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.009_bib42","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A\u00a0randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.009_bib43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/RHU.0000000000000408","article-title":"Ustekinumab as a therapeutic option for children with refractory enthesitis-related arthritis","volume":"22","author":"Mannion","year":"2016","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.009_bib44","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.009_bib45","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s10067-020-05442-4","article-title":"Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data","volume":"40","author":"Wang","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.009_bib46","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-019-2021-9","article-title":"Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts","volume":"21","author":"Colafrancesco","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.009_bib48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.009_bib49","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","article-title":"The Toll-like receptor 4 agonist MRP8\/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis","volume":"71","author":"Holzinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.009_bib50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.rdc.2021.07.009_bib51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.009_bib52","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","article-title":"Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany","volume":"16","author":"Hinze","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib54","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","article-title":"Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans","volume":"15","author":"Kimura","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.009_bib56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.009_bib57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3899\/jrheum.180331","article-title":"Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis","volume":"46","author":"Saccomanno","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.009_bib58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/art.40498","article-title":"IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis","volume":"70","author":"Arthur","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.009_bib59","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/art.41436","article-title":"Efficacy and safety of canakinumab in patients with systemic juvenile idiopathic arthritis with and without fever at baseline: results from an open-label, active-treatment extension study","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.009_bib60","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3899\/jrheum.190011","article-title":"Discontinuation of canakinumab following clinical disease remission is feasible in patients with systemic juvenile idiopathic arthritis","volume":"47","author":"Maritsi","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib61","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/art.41640","article-title":"Distinct gene expression signatures characterize strong clinical responders vs non-responders to Canakinumab in children with sJIA","volume":"73","author":"Verweyen","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.009_bib62","article-title":"A\u00a0dysregulated interleukin-18\/interferon-gamma\/CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis","volume":"keab113","author":"Hinze","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"25","key":"10.1016\/j.rdc.2021.07.009_bib63","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.009_bib64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12969-018-0236-y","article-title":"IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry)","volume":"16","author":"Bielak","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"13","key":"10.1016\/j.rdc.2021.07.009_bib65","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.009_bib66","doi-asserted-by":"crossref","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy","volume":"34","author":"Griffin","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.009_bib67","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.009_bib68","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/art.41488","article-title":"Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from an open-label, randomized phase IIIb\/IV study","volume":"73","author":"Quartier","year":"2021","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21011030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21011030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:21:02Z","timestamp":1760181662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X21011030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0889857X21011030"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.009","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Juvenile Idiopathic Arthritis Treatment Updates","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}